https://ogma.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:42765 2C receptor agonist, has shown potential at reducing the symptoms of substance use disorder. This pilot study (initiated prior to market withdrawal) examined feasibility and safety of lorcaserin treatment in people undergoing residential detoxification and treatment for AUD and MUD. This was an open label pilot study of lorcaserin where participants (n = 10 AUD; n = 8 MUD) received 10-mg lorcaserin daily for 4 days then twice daily for 1 month. Primary outcome measures included recruitment and reten tion rate, incidence of treatment-emergent events, incidence of methamphetamine or alcohol withdrawal-related events, heart rate, and blood pressure. Secondary measures included pharmacokinetic data and self-reported alcohol or methamphetamine use, craving, and psychological distress. AUD participants were recruited faster and had a greater retention rate compared with MUD participants. Lorcaserin did not alter vital signs, was well tolerated, and had a similar pharmacokinetic profile to individuals with obesity. Lorcaserin reduced self-reported alcohol and amphetamine-type sub stance use and craving in AUD and MUD participants, respectively. Self-reported psychological health also improved over the treatment period for all participants. Despite the pilot nature of this study, our data support the notion of 5-HT_2C receptors as a therapeutic target for drug and alcohol abuse.]]> Wed 24 Jul 2024 17:01:25 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:28034 Wed 11 Apr 2018 16:26:21 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:15119 Wed 11 Apr 2018 14:47:31 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:7671 Sat 24 Mar 2018 08:39:24 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:8031 Sat 24 Mar 2018 08:36:47 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:1898 440 msec. Results: There were 469 SSRI poisoning admissions analyzed after exclusions. The median LOS for all SSRI overdose admissions was 15.3 h (IQR: 10.5–21.3) and 30 of 469 (6.4%; 95% CI 4.3–9.0%) cases were admitted to ICU. The incidence of seizures was 1.9% and coma was 2.4%. Serotonin syndrome occurred in 14% of overdoses. Comparison of median QTc intervals of the five SSRIs was significantly different (p = 0.0002); citalopram (450 IQR: 436–484) was individually different to fluoxetine (p = 0.045), fluvoxamine (p = 0.022), paroxetine (p = 0.0002), and sertraline (p = 0.001). The proportion of citalopram overdoses with a QTc > 440 msec was 68%, differing significantly from sertraline (adjusted OR: 5.11 95% CI 2.32–11.27). Comparison of median QT intervals of the five SSRIs was statistically different (p = 0.026); citalopram (400 IQR: 380–440) was individually different from sertraline (p = 0.023). Conclusions: This study shows SSRIs are relatively safe in overdose despite serotonin syndrome being common. The exception was citalopram, which was significantly associated with QTc prolongation. We believe that cardiac monitoring should be considered in citalopram overdose, particularly with large ingestions and patients with associated cardiac disease.]]> Sat 24 Mar 2018 08:33:08 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:10912 Sat 24 Mar 2018 08:07:42 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:29027 Sat 24 Mar 2018 07:31:07 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:25216 Sat 24 Mar 2018 07:13:59 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:49704 Mon 29 May 2023 13:00:55 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:32719 Mon 23 Sep 2019 13:35:30 AEST ]]>